Knife-edge at Elan means no new CEO until bapineuzumab results are in
This article was originally published in Scrip
Executive Summary
Elan's board of directors has announced that instead of leaving the company in May this year as planned (scripintelligence.com, 3 June 2010), Kelly Martin will stay on as CEO until the upcoming completion of a North American Phase III trial of Alzheimer's drug bapineuzumab. The outcome of this trial, and the three other Phase III bapineuzumab trials, are critical to Elan's future direction.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.